Hira, Kenichiro
Ueno, Yuji
Watanabe, Masao
Shimura, Hideki
Kurita, Naohide
Miyamoto, Nobukazu
Haginiwa, Haruna
Yamashiro, Kazuo
Hattori, Nobutaka
Urabe, Takao
Article History
Received: 4 July 2022
Accepted: 30 August 2022
First Online: 8 September 2022
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki. The independent ethics committee of Juntendo University Urayasu Hospital approved this study. As clinical information obtained from medical records was used for all analyses in this study, the need to obtain written informed consent from each patient was waived, which was approved by the independent ethics committee of Juntendo University Hospital.
: NA.
: YU received lecture fees from OHARA Pharmaceutical Co., Ltd., and research funds from Bristol-Myers Squibb. NH was an advisory member of Dai-Nippon Sumitomo Pharma Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Biogen Idec Japan Ltd., received lecture fees from Dai-Nippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., FP Pharmaceutical Corporation, Eisai Co., Ltd., Novartis Pharma K.K., and AbbVie, and received departmental endowments by commercial entities from Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim, Co., Ltd., AbbVie GK, FP Pharmaceutical Corporation, Otsuka Pharmaceutical, Co., Ltd., Dai-Nippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Nihon Medi-physics Co., Ltd., Asahi Kasei Medical Co., Ltd., Ono Pharmaceutical Co., Ltd., MiZ Co., Ltd., AbbVie GK, OHARA Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Boston Scientific Corporation, and Medtronic Inc. TU received lecture fees from AbbVie GK., Daiichi Sankyo Co., Ltd., Boehringer Ingelheim, Otsuka Pharmaceutical Co., Ltd., Bayer Pharmaceutical Co., and AstraZeneca K.K., and research funds from Otsuka Pharmaceutical Co., Ltd., and AbbVie GK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.